Search

Joan M Carboni

from Sarasota, FL
Age ~77
Get Report
Also known as:
Joan Marie Carboni, Joan Marie Carboni Tr, Joan M Boice
Connected to:
Angelo F Carboni, 87Cheryl D Carboni, 77Cynthia A Carboni, 82David M Carboni, 48Erin M Carboni, 43Giuseppe Carboni, 94Guido S Carboni, 95Laura K Carboni, 51Lucas Carboni, 29Michele A Carboni, 82

Joan Carboni Phones & Addresses

  • Sarasota, FL
  • Spring Hill, FL
  • Bronx, NY
  • Princeton, NJ
  • 311 Michael Rd, Morrisville, PA 19067 (215) 295-6771
  • Yardley, PA
  • Meriden, CT
  • Hartford, CT
  • Lawrenceville, NJ
  • 311 Michael Rd, Yardley, PA 19067

Work

Position: Building and Grounds Cleaning and Maintenance Occupations

Education

Degree: Bachelor's degree or higher

Publications

Us Patents

Multivalent Fibronectin Based Scaffold Domain Proteins

View page
US Patent:
8221765, Jul 17, 2012
Filed:
May 22, 2009
Appl. No.:
12/470989
Inventors:
Ray Camphausen - Wayland MA, US
Eric Furfine - Concord MA, US
Irvith M. Carvajal - Brighton MA, US
H. Nicholas Marsh - Charlestown MA, US
Marco Gottardis - Princeton NJ, US
Joan Carboni - Yardley PA, US
Ricardo Attar - Lawrenceville NJ, US
Assignee:
Bristol-Myers Squibb Company - Princeton NJ
International Classification:
A61K 38/17
A61K 47/48
C07K 14/71
C07K 14/435
US Classification:
4241921, 4241923, 514 11, 514 93, 514 192, 530350, 530402
Abstract:
The present invention relates to multivalent polypeptides comprising at least two fibronectin scaffold domains connected via a polypeptide linker. The invention also relates to multivalent polypeptides for use in diagnostic, research and therapeutic applications. The invention further relates to cells comprising such proteins, polynucleotide encoding such proteins or fragments thereof, and to vectors comprising the polynucleotides encoding the innovative proteins.

Bispecific Egfr/Igfir Binding Molecules

View page
US Patent:
8343501, Jan 1, 2013
Filed:
Nov 24, 2009
Appl. No.:
12/625217
Inventors:
Stuart Emanuel - Doylestown PA, US
Linda Engle - Framingham MA, US
Ray Camphausen - Wayland MA, US
Martin C. Wright - Boston MA, US
Ginger Chao - Cambridge MA, US
Marco Gottardis - Princeton NJ, US
Joan Carboni - Yardley PA, US
Assignee:
Bristol-Myers Squibb Company - Princeton NJ
International Classification:
A61K 38/17
A61K 38/39
A61K 47/48
C07K 14/71
C07K 14/435
US Classification:
4241851, 4241931, 514 93, 514 192, 530350, 530402
Abstract:
The present invention relates to bispecific molecules comprising an EGFR binding domain and a distinct IGFIR binding domain for use in diagnostic, research and therapeutic applications. The invention further relates to cells comprising such proteins, polynucleotide encoding such proteins or fragments thereof, and vectors comprising the polynucleotides encoding the innovative proteins. Exemplary bispecific molecules include antibody-like protein dimers based on the tenth fibronectin type III domain.

Biomarkers And Methods For Determining Sensitivity To Insulin Growth Factor-1 Receptor Modulators

View page
US Patent:
8492328, Jul 23, 2013
Filed:
May 15, 2008
Appl. No.:
12/600504
Inventors:
Fei Huang - Princeton NJ, US
Xia Han - Pennington NJ, US
Rameh Hafezi - Franklin Park NJ, US
Jiwen Chen - Bridgewater NJ, US
Douglas Michael Robinson - Hanover MA, US
Gayle M. Wittenberg - Princeton NJ, US
Ashok Ramesh Dongre - Newtown PA, US
Joan M. Carboni - Yardley PA, US
Ricardo M. Attar - Lawrenceville NJ, US
Warren Hurlburt - Mount Laurel NJ, US
Marco M. Gottardis - Princeton NJ, US
Assignee:
Bristol-Myers Squibb Company - Princeton NJ
International Classification:
A01N 61/00
G01N 33/53
US Classification:
514 1, 435 71
Abstract:
IGF1R biomarkers useful in a method for identifying and monitoring a mammal that will respond therapeutically to a method of treating cancer comprising administering an IGF1R modulator, wherein the method comprises (a) exposing the mammal to the IGF1R modulator and (b) measuring in the mammal the level of the at least one biomarker, wherein a difference in the level of the at least one biomarker measured in (b) compared to the level of the biomarker in a mammal that has not been exposed to the IGF1R modulator indicates that the mammal will respond therapeutically to the method of treating cancer and (c) wherein the level of the biomarker in a mammal after exposure to a IGF1R modulator indicates that the mammal has responded therapeutically to the method of treating cancer.

Transgenic Non-Human Mammals Expressing Constitutively Activated Tyrosine Kinase Receptors

View page
US Patent:
20030182668, Sep 25, 2003
Filed:
Mar 3, 2003
Appl. No.:
10/378393
Inventors:
David Bol - Gaithersburg MD, US
Joan Carboni - Yardley PA, US
Ronald Rowley - Guilford CT, US
Tai Wong - Belle Meade NJ, US
Francis Lee - Yardley PA, US
International Classification:
A01K067/027
US Classification:
800/010000, 800/018000
Abstract:
A transgenic non-human mammal whose germ cells and somatic cells contain a constitutively activated tyrosine kinase receptor introduced into the mammal, or an ancestor of the mammal, at an embryonic stage. The transgenic non-human mammals can be used as ligand-independent in vivo models for the identification and development of selective tyrosine kinase modulators for the treatment of cancer.

Synergistic Methods And Compositions For Treating Cancer

View page
US Patent:
20040072760, Apr 15, 2004
Filed:
Oct 1, 2003
Appl. No.:
10/677067
Inventors:
Joan Carboni - Yardley PA, US
Warren Hurlburt - Mount Laurel NJ, US
Marco Gottardis - Princeton NJ, US
International Classification:
A61K038/08
A61K031/538
A61K031/57
A61K031/198
A61K031/4745
A61K031/427
US Classification:
514/017000, 514/018000, 514/182000, 514/283000, 514/365000, 514/449000, 514/229500, 514/546000
Abstract:
Methods of using IGF1R inhibitors in combination with cytotoxic agents are described for the synergistic treatment of cancer.

Synergistic Methods And Compositions For Treating Cancer

View page
US Patent:
20040106605, Jun 3, 2004
Filed:
Oct 1, 2003
Appl. No.:
10/676214
Inventors:
Joan Carboni - Yardley PA, US
Warren Hurlburt - Mount Laurel NJ, US
Marco Gottardis - Princeton NJ, US
International Classification:
A61K031/54
A61K031/513
A61K031/4439
US Classification:
514/226800, 514/228200, 514/269000, 514/338000
Abstract:
The use of IGF1R inhibitors in combination with EGFR inhibitors are described for the synergistic treatment of cancer.

Synergistic Methods And Compositions For Treating Cancer

View page
US Patent:
20040209930, Oct 21, 2004
Filed:
Mar 31, 2004
Appl. No.:
10/814199
Inventors:
Joan Carboni - Yardley PA, US
Warren Hurlburt - Mount Laurel NJ, US
Marco Gottardis - Princeton NJ, US
Francis Lee - Yardley PA, US
International Classification:
A61K031/426
US Classification:
514/370000
Abstract:
Combination therapies using IGF1R inhibitors in combination with additional kinase inhibitors are described for the synergistic treatment of cancer.

Methods For Treating Igf1R-Inhibitor Induced Hyperglycemia

View page
US Patent:
20050075358, Apr 7, 2005
Filed:
Oct 5, 2004
Appl. No.:
10/958869
Inventors:
Joan Carboni - Yardley PA, US
Ricardo Attar - Lawrenceville NJ, US
Marco Gottardis - Princeton NJ, US
Jean Whaley - Bedminster NJ, US
Thomas Harrity - Middlesex NJ, US
International Classification:
A61K031/513
A61K031/4439
A61K031/426
A61K031/4184
A61K031/155
US Classification:
514269000, 514338000, 514394000, 514342000, 514369000, 514636000
Abstract:
Methods for treating cancer using IGF1R inhibitors in combination with insulin sensitizers are provided for the treatment or prevention of hyperglycemia.
Control profile
Joan M Carboni from Sarasota, FL, age ~77 Get Report